Psychiatric Multi-omics and Neuroimaging Project (PMNP)

Psychiatric Multi-omics and Neuroimaging Project Database

This study focuses on the structure and function of the brain and gene expression in peripheral blood of patients with schizophrenia, to explore the interaction and influence between the three. Patients with mental disorders who have been recruited will take their medication regularly for 1 year and participate in baseline and follow-up assessments.

Study Overview

• Status: Recruiting
• Conditions: Mental Disorders; Healthy Control
• Intervention / Treatment: Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids

Detailed Description

The study seeks to identify possible biological markers of schizophrenia and the effects of gene-environment interactions on brain structural and functional networks. So we can help doctors and scientific researchers better understand the neuropathological basis of schizophrenia.

• Study Type: Observational
• Enrollment (Estimated): 1899

Contacts and Locations

• Study Contact: Name: Yunzhi Pan; Phone Number: 15074818197; Email: panyunzhi@csu.edu.cn

Study Locations

• China
  • Hunan
    • Changsha, Hunan, China, 410000
      • Recruiting
      • The Second Xiangya hospital of central south univerity
      • Contact: Yunzhi Pan; Phone Number: 15074818197; Email: panyunzhi@csu.edu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Probability Sample

Study Population

Patients from inpatient and outpatient the second Xiangya Hosptial of Central South University, Healthy controls from community, school and street recruitment

Description

Inclusion Criteria:

• Age: 13-35 years old(Patients with healthy siblings can be extended to 14-35 years of age)
• Course of disease: <24 months
• Priority is given to patients who have never taken medicine or duration of drug use < 2 weeks
• No nuclear magnetic contraindications.

Exclusion Criteria:

• Family history of psychotic disorders, history of psychoactive substances abuse, alcohol dependence, or nicotine dependence
• Have a major physical disease or infectious disease
• History of coma and serious neurological disease 4.MRI contraindications.

Study Plan

How is the study designed?

Number of groups / cohorts

6

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
PMNP-Healthy Norms; Healthy Norms	Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids; Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.
PMNP-Subclinical high-risk; Subclinical high-risk	Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids; Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.
PMNP-Schizophrenia and Psychosis; Schizophrenia and Psychosis patient	Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids; Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.
PMNP-MDD; major depressive disorder patient	Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids; Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.
PMNP-ASD; autism spectrum disorder patient	Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids; Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.
PMNP-BD; bipolar disorder patient	Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids; Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
cortical morphology	Data were obtained using magnetic resonance scans	40 minutes
target gene charaacteristics	10ml peripheral blood was extracted for gene analysis	1 day
scale scores	The score of each dimension and the total score were calculated according to the scale.The scale includes three dimensions: negative symptom, positive symptom and general psychopathology, and the score range of each dimension is different. The total score ranges from 30 to 210, with higher scores indicating worse results.	90 minutes.

Collaborators and Investigators

• Sponsor: mingjun Zhong

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2016
• Primary Completion (Estimated): January 1, 2027
• Study Completion (Estimated): January 1, 2027

Study Registration Dates

• First Submitted: August 28, 2024
• First Submitted That Met QC Criteria: August 29, 2024
• First Posted (Actual): August 30, 2024

Study Record Updates

• Last Update Posted (Actual): March 13, 2026
• Last Update Submitted That Met QC Criteria: March 11, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: magnetic resonance imaging; schizophrenia; bipolar disorder; autism spectrum disorder; major depressive disorder; multi-omics
• Additional Relevant MeSH Terms: Bipolar and Related Disorders; Schizophrenia Spectrum and Other Psychotic Disorders; Mood Disorders; Neurodevelopmental Disorders; Child Development Disorders, Pervasive; Depressive Disorder; Autism Spectrum Disorder; Schizophrenia; Bipolar Disorder; Mental Disorders; Depressive Disorder, Major; Physiological Effects of Drugs; Central Nervous System Depressants; Tranquilizing Agents; Psychotropic Drugs; Pharmacologic Actions; Chemical Actions and Uses; Therapeutic Uses; Central Nervous System Agents; Antipsychotic Agents; Antidepressive Agents
• Other Study ID Numbers: NSFC82201664

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No